A
Arcus Biosciences, Inc. (RCUS)
NYQ – Real Time Price. Currency in USD
31.00
+0.75 (2.48%)
At close: Jun 26, 2026, 4:00 PM EDT
31.36
+0.36 (1.16%)
After-hours: Jun 26, 2026, 5:57 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
31.00
+0.75 (2.48%)
At close: Jun 26, 2026, 4:00 PM EDT
31.36
+0.36 (1.16%)
After-hours: Jun 26, 2026, 5:57 PM EDT
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Name | Position |
|---|---|
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer |
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO |
| Mr. Alexander Azoy CPA | Chief Accounting Officer |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary |
| Ms. Jennifer A. Jarrett M.B.A. | Advisor |
| Pia Eaves | Vice President of Investor Relations & Strategy |
| Date | Type | Document |
|---|---|---|
| 2026-06-12 | 8-K | rcus-20260611.htm |
| 2026-05-05 | 8-K | rcus-20260505.htm |
| 2026-05-05 | 10-Q | rcus-20260331.htm |
| 2026-04-21 | DEFA14A | arcusfy2026proxynotice.htm |
| 2026-04-21 | DEF 14A | rcus-20260421.htm |
| 2026-04-21 | ARS | fy2025annualreporttoshareh.pdf |
| 2026-04-20 | 8-K | rcus-20260420.htm |
| 2026-03-23 | 8-K | rcus-20260317.htm |
| 2026-02-25 | S-8 | rcus_fyx2026xs-8.htm |
| 2026-02-25 | S-3ASR | d274489ds3asr.htm |